Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the first patient has been dosed in the Phase I dose escalation portion of a company-sponsored Phase I/II trial of BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the first patient has been dosed in the Phase IIa expansion portion of the Phase I/IIa trial sponsored by Cancer Research UK, the world’s leading cancer charity dedicated to saving lives through research. The trial is evaluating BT1718 in patients with MT1-MMP-positive squamous non-small cell lung cancer (NSCLC) and a basket of other MT1-MMP-positive solid tumors.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of Dominic Smethurst, MA, MBChB, MRCP, MFPM as Chief Medical Officer. Dr. Smethurst brings to Bicycle extensive expertise in developing bispecific immuno-oncology agents, as well as toxin conjugate therapeutics for cancer and other serious diseases.
“Given his in-depth knowledge of conventional and disruptive therapeutic modalities, we believe Dominic is uniquely qualified to guide development of Bicycles as potential solutions to many of the limitations faced by small molecule and antibody-based medicines”
With an already extensive portfolio of successful cases across industries and a wide variety of AI-driven robotics solutions, Geek+ is partnering up with Kuecker Logistics Group (KLG), a material handling systems integrator, to provide smart logistics solutions to customers across North America. Geek+ will enable an upgrade of the system integrator’s already broad range of services provided, from supply chain management and industrial automation to life cycle services and more.
TARANIS, an ag-tech startup that uses aerial surveillance and machine learning to help prevent crop-yield loss, said on Wednesday that it has raised US$30 million in a Series C round led by Vertex Growth and Kuok Group’s Orion Fund (managed by K3 Ventures).
Tam Hock Chuan, managing director of Vertex Growth said: “The adoption of Taranis’ solutions will help growers and crop consultants to detect, analyse and treat crop issues at their earliest signs, taking preventive measures with unprecedented precision. This will give them a higher degree of control over their crop yield than ever before, particularly relevant in Asia where the agriculture sector has a relatively lower yield per hectare compared to global benchmarks.”
Geek+, a global AMR leader is pleased to announce it has extended its cooperation with Decathlon, one of the world's largest retailers of sporting goods, present in over 50 countries with more than 1,600 stores globally. Following the success of a two-year collaboration in its e-commerce and retail fulfillment centers in Shanghai, Decathlon accelerated its automation program, with AMR deployments at two new sites in China. The installations were successfully deployed remotely in under 3 months, following strict pandemic restrictions.